In vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones (Q39834358)

15 September 2017

In vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones (English)

1 reference

15 September 2017

Stamm JM

1

1 reference

15 September 2017

Hanson CW

2

1 reference

15 September 2017

Chu DT

3

1 reference

15 September 2017

Bailer R

4

1 reference

15 September 2017

Vojtko C

5

1 reference

15 September 2017

Fernandes PB

6

1 reference

15 September 2017

language of work or name

English

0 references

publication date

1 February 1986

1 reference

Antimicrobial Agents and Chemotherapy

15 September 2017

1 reference

15 September 2017

29

1 reference

15 September 2017

2

1 reference

15 September 2017

193-200

1 reference

In vitro and in vivo activity of DL-8280, a new oxazine derivative

15 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=176376

In vitro antibacterial activity of AM-715, a new nalidixic acid analog

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=176376

In vitro susceptibilities of 393 recent clinical isolates to WIN 49375, cefotaxime, tobramycin, and piperacillin

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=176376

Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=176376

Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=176376

In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=176376

In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=176376

Antagonists of Nucleic Acid Derivatives Viii. Synergism in Combinations of Biochemically Related Antimetabolites

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=176376

Pharmacokinetics and tissue penetration of ciprofloxacin

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=176376

The in vitro and in vivo activity of ciprofloxacin

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=176376

In-vitro studies with ciprofloxacin, a new 4-quinolone compound.

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=176376

Norfloxacin (MK-0366, AM-715): In vitro activity and cross-resistance with other organic acids including quality control limits for disk diffusion testing

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=176376

In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=176376

Antibacterial activity of norfloxacin

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=176376

Norfloxacin: activity against urinary tract pathogens and factors influencing the emergence of resistance

20 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/3087274

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

[A new synthetic antibacterial : 1-ethyl-6-fluoro-7-(4-methyl-1-piperazinyl)-4-oxo-1, 4-dihydroquinolin-3-carboxylic acid (1589 R.B.)]

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/3087274

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

[Structure-activity relationships in the quinolone group: antibacterial activity of two new compounds (author's transl)]

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/3087274

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1128/AAC.29.2.193

1 reference

15 September 2017

1 reference

15 September 2017

PubMed publication ID

3087274

1 reference